{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:42:44Z","timestamp":1793572964138,"version":"4.5.0"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>ELIOS (NCT03239340) prospectively compared tumor biopsies obtained pre-treatment and post-progression to characterize acquired resistance mechanisms to first-line osimertinib in epidermal growth factor receptor (EGFR)-mutant advanced non\u2013small cell lung cancer (NSCLC). Of 154 patients enrolled, 52 patients had next-generation sequencing (NGS) results from paired tissue biopsies. The most common acquired alterations at progression were MET amplification (17%), deletion of CDKN2A\/CDKN2B (15%) and MTAP (13%), and EGFR C797S (13%). Proteogenomic analysis (n = 32 at baseline and n = 18 post-progression) showed TROP2 was highly expressed at baseline and post-progression, irrespective of genetic alterations observed. In a separate analysis of patients with matched tissue and plasma samples post-progression (n = 51), 82% had potential resistance alterations by NGS, demonstrating the complementary roles of tissue and plasma NGS. These results highlight the challenges of obtaining tissue biopsies in patients with NSCLC progressing on targeted therapy, the potential for heterogeneous resistance, and the need for broad-acting treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>ELIOS confirmed acquired resistance mechanisms to first-line osimertinib in a prospective, molecular profiling study of paired pre- and post-treatment tissue samples and provided the first proteogenomic characterization before\/after osimertinib, identifying novel proteomic markers. ELIOS showed the potential for heterogeneous resistance, highlighting that strategies targeting multiple resistance pathways may be required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-0960","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:02:28Z","timestamp":1772809348000},"page":"1074-1086","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["ELIOS: A Multicenter, Molecular Profiling Study of Patients with\n                    <i>EGFR<\/i>\n                    -Mutant Advanced Non\u2013Small Cell Lung Cancer Treated with First-Line Osimertinib"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-8573","authenticated-orcid":false,"given":"Zofia","family":"Piotrowska","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 1 Department of Medicine, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9654","authenticated-orcid":false,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a15z872","id-type":"ROR","asserted-by":"publisher"}],"name":"Samsung Medical Center 2 Department of Hematology and Oncology, , Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-9860","authenticated-orcid":false,"given":"Pei Jye","family":"Voon","sequence":"additional","affiliation":[{"name":"3Radiotherapy and Oncology Department, Hospital Umum Sarawak, Kuching, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-8928","authenticated-orcid":false,"given":"Yong-Kek","family":"Pang","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-6477","authenticated-orcid":false,"given":"Soon Hin","family":"How","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03s9hs139","id-type":"ROR","asserted-by":"publisher"}],"name":"International Islamic University Malaysia 5 Department of Medicine, Kulliyyah of Medicine, , Kuantan, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-8095","authenticated-orcid":false,"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[{"name":"6Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-7369","authenticated-orcid":false,"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[{"name":"7Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy."},{"name":"8Department of Medicine, University Milano-Bicocca, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-6306","authenticated-orcid":false,"given":"Javier","family":"de Castro Carpe\u00f1o","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz 9 Department of Medical Oncology, , CIBERONC, IdiPAZ, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-8465","authenticated-orcid":false,"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"10Department of Medicine and Surgery, University of Parma, Parma, Italy."},{"name":"11Medical Oncology Unit, University Hospital of Parma, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-1366","authenticated-orcid":false,"given":"Delvys","family":"Rodr\u00edguez Abreu","sequence":"additional","affiliation":[{"name":"12Department of Medical Oncology, Gran Canaria University Hospital, Las Palmas de Gran Canaria, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3652-8009","authenticated-orcid":false,"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca (United States) 14 Global Medical Affairs, Oncology Business Unit, , Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3121-8238","authenticated-orcid":false,"given":"Leslie","family":"Servidio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca (United States) 14 Global Medical Affairs, Oncology Business Unit, , Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5506-8924","authenticated-orcid":false,"given":"Rosemary","family":"Taylor","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04r9x1a08","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca (United Kingdom) 15 Oncology Biometrics, , Macclesfield, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7416-6036","authenticated-orcid":false,"given":"Ryan","family":"Hartmaier","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca (United States) 16 Translational Medicine, Research and Early Development, Oncology R&D, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-0424","authenticated-orcid":false,"given":"Aleksandra A.","family":"Markovets","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca (United States) 17 Oncology Data Science, Research and Early Development, Oncology R&D, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-5159","authenticated-orcid":false,"given":"Kwan Ho","family":"Tang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca (United States) 16 Translational Medicine, Research and Early Development, Oncology R&D, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"18Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026060103134451900_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"2026060103134451900_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026060103134451900_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026060103134451900_bib4","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060103134451900_bib5","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060103134451900_bib6","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060103134451900_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060103134451900_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"2026060103134451900_bib9","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1200\/JCO-25-01061","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025.1","volume":"43","author":"Reuss","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060103134451900_bib10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"2026060103134451900_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"2026060103134451900_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"2026060103134451900_bib13","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026060103134451900_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib15","doi-asserted-by":"crossref","first-page":"e1812","DOI":"10.1002\/onco.13889","article-title":"Plasma cell-free DNA genotyping: from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer","volume":"26","author":"Gray","year":"2021","journal-title":"Oncologist"},{"key":"2026060103134451900_bib16","doi-asserted-by":"crossref","first-page":"11795549221116834","DOI":"10.1177\/11795549221116834","article-title":"Concordance of genomic profiles in matched tissue and plasma samples from Chinese patients with lung cancer","volume":"16","author":"He","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"2026060103134451900_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"issue":"12_Supplement","key":"2026060103134451900_bib18","doi-asserted-by":"crossref","first-page":"LB078","DOI":"10.1158\/1538-7445.AM2022-LB078","article-title":"Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the phase II ORCHARD study","volume":"82","author":"Hartmaier","year":"2022","journal-title":"Cancer Res"},{"key":"2026060103134451900_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"2026060103134451900_bib20","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026060103134451900_bib21","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026060103134451900_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib23","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1172\/JCI64048","article-title":"Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung","volume":"122","author":"Maeda","year":"2012","journal-title":"J Clin Invest"},{"key":"2026060103134451900_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"2026060103134451900_bib25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.molcel.2025.03.001","article-title":"Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma","volume":"85","author":"Pulice","year":"2025","journal-title":"Mol Cell"},{"key":"2026060103134451900_bib26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib27","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib28","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2025.43.16_suppl.8507","article-title":"Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): results from the randomized OptiTROP-Lung03 study","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060103134451900_bib29","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026060103134451900_bib30","volume-title":"FDA grants breakthrough therapy designation to Sac-TMT for previously treated NSCLC","author":"McGovern","year":"2024"},{"key":"2026060103134451900_bib31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"2026060103134451900_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat Commun"},{"key":"2026060103134451900_bib33","first-page":"100525","article-title":"Analysis of tumor heterogeneity through AXL activation in primary resistance to EGFR tyrosine kinase inhibitors","volume":"4","author":"Nakamura","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"2026060103134451900_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026060103134451900_bib35","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J Med Chem"},{"issue":"16_suppl","key":"2026060103134451900_bib36","doi-asserted-by":"crossref","first-page":"TPS9142","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9142","article-title":"A phase 1\/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non\u2013small cell lung cancer (NSCLC)","volume":"40","author":"Spira","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060103134451900_bib37","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jtho.2022.07.118","article-title":"MA07.09 BBT-176, a 4th generation EGFR TKI, for progressed NSCLC after EGFR TKI therapy: PK, safety and efficacy from phase 1 study","volume":"17","author":"Lim","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib38","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jtho.2017.08.006","article-title":"Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer","volume":"12","author":"Arulananda","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)","volume":"22","author":"Yu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2026060103134451900_bib40","first-page":"100179","article-title":"EML4-ALK rearrangement as a mechanism of resistance to osimertinib in metastatic lung adenocarcinoma: a case report","volume":"2","author":"von Buttlar","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2026060103134451900_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-021-00149-4","article-title":"Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant\/BRAF V600E lung adenocarcinoma patient","volume":"5","author":"Ribeiro","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026060103134451900_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026060103134451900_bib43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"key":"2026060103134451900_bib44","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2025.10.009","article-title":"Osimertinib plus savolitinib in patients with EGFR-mutated advanced NSCLC with MET alterations after first-line osimertinib: clinical outcomes, safety, and biomarker analysis: a brief report","volume":"21","author":"Le","year":"2026","journal-title":"J Thorac Oncol"},{"key":"2026060103134451900_bib45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026060103134451900_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13046-021-01940-8","article-title":"Current status of ctDNA in precision oncology for hepatocellular carcinoma","volume":"40","author":"Li","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026060103134451900_bib47","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1158\/1078-0432.CCR-24-0466","article-title":"Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling","volume":"30","author":"El Zarif","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026060103134451900_bib48","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026060103134451900_bib49","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"7_Supplement","key":"2026060103134451900_bib50","doi-asserted-by":"crossref","first-page":"CT017","DOI":"10.1158\/1538-7445.AM2024-CT017","article-title":"Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed","volume":"84","author":"J\u00e4nne","year":"2024","journal-title":"Cancer Res"},{"key":"2026060103134451900_bib51","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.cllc.2022.07.019","article-title":"Study design and rationale for the PACE-LUNG trial: a multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment","volume":"23","author":"Acker","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2026060103134451900_bib52","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer","volume":"41","author":"de Miguel","year":"2023","journal-title":"Cancer Cell"},{"key":"2026060103134451900_bib53","doi-asserted-by":"crossref","first-page":"1618509","DOI":"10.3389\/fonc.2025.1618509","article-title":"NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort","volume":"15","author":"Kowalewski","year":"2025","journal-title":"Front Oncol"},{"key":"2026060103134451900_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11523-025-01166-0","article-title":"MET alterations in cancer and MET-targeted therapy: detection strategies, treatment efficacy, and emerging technologies","volume":"20","author":"Park","year":"2025","journal-title":"Target Oncol"},{"key":"2026060103134451900_bib55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1559-0275-9-5","article-title":"Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue","volume":"9","author":"Hembrough","year":"2012","journal-title":"Clin Proteomics"},{"key":"2026060103134451900_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-019-03358-x","article-title":"Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival","volume":"146","author":"Schaff","year":"2020","journal-title":"J Neurooncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-0960\/3746030\/cd-25-0960.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-0960\/3789855\/cd-25-0960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/6\/1074\/3799166\/cd-25-0960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/6\/1074\/3799166\/cd-25-0960.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:13:59Z","timestamp":1780298039000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/6\/1074\/785550\/ELIOS-A-Multicenter-Molecular-Profiling-Study-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-0960","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8509469","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.32530880","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530886","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530883","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}